Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.12)
# 2,745
Out of 4,847 analysts
23
Total ratings
50%
Success rate
5.39%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $20.66 | +50.08% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.30 | +135.85% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $10.22 | +22.31% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.63 | +268.10% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.40 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $11.79 | +112.04% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $240 | $4.25 | +5,547.06% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $16.54 | +383.68% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $6.39 | +259.94% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $0.92 | +2,512.67% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.78 | +112,259.55% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.93 | - | 1 | Sep 27, 2017 | |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $20.66
Upside: +50.08%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.30
Upside: +135.85%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $10.22
Upside: +22.31%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.63
Upside: +268.10%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $11.79
Upside: +112.04%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $240
Current: $4.25
Upside: +5,547.06%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $16.54
Upside: +383.68%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $6.39
Upside: +259.94%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $0.92
Upside: +2,512.67%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.78
Upside: +112,259.55%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.93
Upside: -